IODM Partners with TransferMate for 283 US University Rollout, Boosts Convera Revenue Share

IODM expands into US higher ed with 283 universities via TransferMate; Convera UK deal ups revenue share to 30% as AUD 1m funding backs expansion.

IC
Isla Campbell
·1 min read
IODM Partners with TransferMate for 283 US University Rollout, Boosts Convera Revenue Share

Key points

  • Major US university software deal via TransferMate

  • Improved revenue share terms with Convera (UK)

  • Execution and funding remain key investor concerns

IODM Ltd (ASX: IOD) has secured a significant expansion into the US higher education market through a partnership with TransferMate, aiming to offer its IODM Connect platform to 283 universities.

This marks a substantial step into the US higher education sector for the company.

The rollout will utilise a one-to-many implementation approach, a method expected to accelerate the scaling of operations in North America compared to individual university onboarding.

The company anticipates revenue share recognition from October 2026.

IODM has forecast a minimum implementation rate of five universities per month for FY2027, with this rate expected to increase as the onboarding process progresses.

To support the anticipated resourcing requirements for this expansion, IODM has secured a AUD 1 million funding agreement for a term of six months at an interest rate of 9.6% per annum.

Improved Convera UK Agreement Terms

In addition to its US expansion, IODM has renewed its commercial agreement with Convera (UK) for the UK higher education sector, effective 1 April 2026.

Under the renewed agreement, IODM's revenue share has increased to 30% of all payments revenue for all universities using IODM.

This represents an uplift from the previous terms, which saw IODM receive a 25% revenue share for five existing/original universities.

The agreement is now on a non-exclusive basis within the UK and Europe.

However, IODM is restricted from working with other payment companies for universities that are already identified within the implementation pipeline.

Financial Health and Going Concern

The latest half-yearly report to 31 December 2025 indicated a 33% increase in revenue, but the company continued to report net losses.

Liquidity improved materially during the period, with borrowings fully converted to equity and cash increasing to AUD 570,000.

Despite these improvements, the auditor's review included a material uncertainty related to going concern.

This highlights the company's reliance on forecast sales or additional funding to continue operations, a point that directors believe can be managed for at least 12 months.

Funding and Dilution Risk

The recently secured AUD 1 million funding agreement, with a 6-month term at 9.6% per annum, is designed to support the accelerated rollout in the US market.

An important aspect of this funding is the lender's ability to elect repayment in shares.

This share repayment option is fixed at a price of $0.156 per share.

Should the lender choose to convert, this could introduce potential dilution risk for existing shareholders.

Stay Informed

Get the latest ASX small-cap news, exclusive interviews, and market insights delivered to your inbox weekly.

Join 100,000+ investors. Unsubscribe anytime.

More Like This

View All